论文部分内容阅读
目的:研究奈比洛尔在心衰和非心衰的心肌细胞中对一氧化氮合酶(eNOS)活性的影响。方法:采用免疫组化的方法测定应用奈比洛尔、卡维地洛和美托洛尔等药物后人、鼠心室心肌细胞中eNOS蛋白水平移位及eNOSser1177磷酸化结果。结果:与未加药物的对照组比较,应用奈比洛尔后,非心衰受试者的心室心肌细胞中的eNOS移位及eNOSSer1177磷酸化未见明显差异(P>0.1) ;与用药前比较,2种指标在非心衰大鼠心肌细胞中用药后也未见明显差异(P>0.1) ,但在心衰受试者的左室心肌细胞中,可见2种指标明显受抑(P≤0.05)。卡维地洛、美托洛尔在所有心肌组织中均不影响eNOS活性。结论:奈比洛尔不影响非心衰的左室心肌细胞eNOS活性,但可抑制心衰细胞eNOS活性,由此发挥其不同的有益的临床作用。
AIM: To investigate the effect of nebivolol on nitric oxide synthase (eNOS) activity in heart failure and non-heart failure. Methods: Immunohistochemical method was used to determine eNOS protein level and eNOSser1177 phosphorylation in human and rat ventricular myocytes after nebivolol, carvedilol and metoprolol. Results: Compared with the control group without nebivolol, eNOS translocation and eNOSSer1177 phosphorylation of ventricular myocytes in non-heart failure subjects showed no significant difference (P> 0.1) compared with those before drug treatment . There was no significant difference between the two indexes in cardiomyocytes of non-heart failure rats (P> 0.1). However, in the left ventricular myocytes of heart failure patients, the two indexes were significantly inhibited (P≤ 0.05). Carvedilol and metoprolol did not affect eNOS activity in all myocardial tissues. Conclusion: Nebivolol has no effect on eNOS activity in non-heart-failure of left ventricular myocytes but inhibits eNOS activity in heart failure cells, thus exerting different beneficial clinical effects.